³í¹®
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma (DIAGNOSTIC PATHOLOGY)
Ultrasound and MRI Findings of Giant Cell Fibroblastoma in the Abdominal Wall: Radiologic-Pathologic Correlations / º¹º®¿¡ ¹ß»ýÇÑ °Å´ë¼¼Æ÷ ¼¶À¯¾Æ¼¼Æ÷Á¾ÀÇ ÃÊÀ½ÆÄ¿Í ÀÚ±â°ø¸í¿µ»ó ¼Ò°ß: ¿µ»ó¼Ò°ß°ú º´¸®ÇÐÀû ¼Ò°ßÀÇ ºñ±³ (´ëÇÑ¿µ»óÀÇÇÐȸÁö)
BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis (Pathology Research and Practice)
Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets (HUMAN PATHOLOGY)
Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer (Pathology Research and Practice)
Treatment for gastric 'indefinite for neoplasm/dysplasia' lesions based on predictive factors (WORLD JOURNAL OF GASTROENTEROLOGY)
Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations (BMC CANCER)
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer (CANCER RESEARCH AND TREATMENT)
Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition (HUMAN PATHOLOGY)
Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11 (GASTRIC CANCER)